Apolipoprotein E, smooth muscle cells and the pathogenesis of cerebral amyloid angiopathy: The potential pole of impaired cerebrovascular Aβ clearance

Annals of the New York Academy of Sciences

Volumn 903, Issue , 2000, Pages 180-186

  Prior, Reinhard ^a   Wihl, Günther ^a   Urmoneit, Britta ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEOHEPARAN SULFATE; SCAVENGER RECEPTOR;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CONFERENCE PAPER; ENDOSOME; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GENOTYPE; HUMAN; LYSOSOME; PATHOGENESIS; PERICYTE; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR AMYLOIDOSIS;

EID: 0034016989     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06367.x     Document Type: Conference Paper

References (24)

1. 1. CALHOUN, M.E. et al. 1999. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc. Natl. Acad. Sci. USA 96: 14088-14093.
2. 2. LADU, M.J. et al. 1994. Isoform-specific binding of apolipoprotein E to beta-amyloid. J. Biol. Chem. 269: 23403-23406.
3. 3. JORDAN, J. et al. 1998. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J. Neurosci. 18: 195-204.
4. 4. JI, Z.S. et al. 1998. Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than E4. J. Biol. Chem. 273: 13452-13460.
5. 5. BEFFERT, U. et al. 1999. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures. Brain Res. Mol. Brain Res. 68: 181-185.
6. 6. PRIOR, R. et al. 1996. Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques. Am. J. Pathol. 148: 1749-1756.
7. 7. PRIOR, R. et al. 1995. Experimental deposition of Alzheimer amyloid beta-protein in canine leptomeningeal vessels. Neuroreport 6: 1747-1751.
8. 8. URMONEIT, B. et al. 1997. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy. Lab. Invest. 77: 157-166.
9. 9. STRITTMATTER, W.J. et al. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. USA 90: 1977-1981.
10. 10. WISNIEWSKI, T. et al. 1993. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 192: 359-365.
11. 11. VIGO-PELFREY, C. et al. 1993. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem. 61: 1965-1968.
12. 12. ALONZO, N.C. et al. 1998. Progression of cerebral amyloid angiopathy: accumulation of amyloid-beta40 in affected vessels. J. Neuropathol. Exp. Neurol. 57: 353-359.
13. 13. GRAVINA, S.A. et al. 1995. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem. 270: 7013-7016.
14. 14. SHINKAI, Y. et al. 1997. Amyloid beta-protein deposition in the leptomeninges and cerebral cortex. Ann. Neurol. 42: 899-908.
15. 15. SUZUKI, N. et al. 1994. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am. J. Pathol. 145: 452-460.
16. 16. SHINKAI, Y. et al. 1995. Amyloid beta-proteins 1-40 and 1-42(43) in the soluble fraction of extra-and intracranial blood vessels. Ann. Neurol. 38: 421-428.
17. 17. HOLTZMAN, D.M. et al. 1999. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103: R15-R21.
18. 18. HARPER, J.D. & P.T. LANSBURY, JR. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 66: 385-407.
19. 19. ALESHKOV, S. et al. 1997. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 36: 10571-10580.
20. 20. SNOW, A.D. et al. 1988. The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease. Am. J. Pathol. 133: 456-463P.
21. 21. SNOW, A.D. et al. 1994. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 12: 219-234.
22. 22. SNOW, A.D. et al. 1995. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320: 84-95.
23. 23. CASTILLO, G.M. et al. 1997. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem. 69: 2452-2465.
24. 24. VAN NOSTRAND, W.E. et al. 1998. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J. Neurochem. 70: 216-223.